5‐azacitidine restores and amplifies the bicalutamide response on preclinical models of androgen receptor expressing or deficient prostate tumors

Epigenetic modifications play a key role in the in prostate cancer (Pca) progression to a hormone refractory state (HRPC) and the current use of agents targeting epigenetic changes has become a topic of intense interest in cancer research. In this regard, 5‐Azacitine (5‐Aza) represents a promising epigenetic modulator. This study tested the hypothesis that 5‐Aza may restore and enhance the responsiveness of HRPC cells to anti‐hormonal therapy on Androgen receptor (AR) expressing (22rv1) and AR‐deficient (PC3) cells.

[1]  M. Naumann,et al.  Helicobacter pylori-induced activation of β-catenin involves low density lipoprotein receptor-related protein 6 and Dishevelled , 2010, Molecular Cancer.

[2]  Xianglin L. Du,et al.  Review of major adverse effects of androgen‐deprivation therapy in men with prostate cancer , 2009, Cancer.

[3]  Vincenza Dolo,et al.  Azacitidine improves antitumor effects of docetaxel and cisplatin in aggressive prostate cancer models. , 2009, Endocrine-related cancer.

[4]  F. Marincola,et al.  AAAS joins the Translational Medicine family , 2009, Journal of Translational Medicine.

[5]  G. Bossi,et al.  MEK/ERK inhibitor U0126 affects in vitro and in vivo growth of embryonal rhabdomyosarcoma , 2009, Molecular Cancer Therapeutics.

[6]  D. Tindall,et al.  Induction of FLIP expression by androgens protects prostate cancer cells from TRAIL‐mediated apoptosis , 2008, The Prostate.

[7]  Massimo Libra,et al.  Targeting prostate cancer based on signal transduction and cell cycle pathways , 2008, Cell cycle.

[8]  Richard J Lee,et al.  Nerve Growth factor regulation of cyclin D1 in PC12 cells through a p21RAS extracellular signal-regulated kinase pathway requires cooperative interactions between Sp1 and nuclear factor-kappaB. , 2008, Molecular biology of the cell.

[9]  T. Murphy,et al.  The emergence of DNA methylation as a key modulator of aberrant cell death in prostate cancer. , 2008, Endocrine-related cancer.

[10]  G. Sonpavde,et al.  Phase II study of azacitidine to restore responsiveness of prostate cancer to hormonal therapy. , 2007, Clinical genitourinary cancer.

[11]  H. Abdulhaq,et al.  The role of azacitidine in the treatment of myelodysplastic syndromes , 2007, Expert opinion on investigational drugs.

[12]  Andreas Schätzlein,et al.  Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  A. D. De Marzo,et al.  Abnormal DNA methylation, epigenetics, and prostate cancer. , 2007, Frontiers in bioscience : a journal and virtual library.

[14]  R. Kuefer,et al.  5-Aza-2′-Deoxycytidine Delays Androgen-Independent Disease and Improves Survival in the Transgenic Adenocarcinoma of the Mouse Prostate Mouse Model of Prostate Cancer , 2007, Clinical Cancer Research.

[15]  M. Fassan,et al.  Molecular genetics of prostate cancer: clinical translational opportunities. , 2007, Journal of experimental & clinical cancer research : CR.

[16]  J. Issa,et al.  Phase II study of low‐dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia , 2007, Cancer.

[17]  M. Nevalainen,et al.  The functional significance of nuclear receptor acetylation , 2007, Steroids.

[18]  Ming Zhao,et al.  Phase I Study of Decitabine-Mediated Gene Expression in Patients with Cancers Involving the Lungs, Esophagus, or Pleura , 2006, Clinical Cancer Research.

[19]  C. Ciccarelli,et al.  Down-regulation of c-Myc following MEK/ERK inhibition halts the expression of malignant phenotype in rhabdomyosarcoma and in non muscle-derived human tumors , 2006, Molecular Cancer.

[20]  A. Dueñas-González,et al.  Journal of Translational Medicine Global Dna Hypermethylation-associated Cancer Chemotherapy Resistance and Its Reversion with the Demethylating Agent Hydralazine , 2022 .

[21]  Kelly B. Moran,et al.  Phase I Trial of Sequential Low-Dose 5-Aza-2′-Deoxycytidine Plus High-Dose Intravenous Bolus Interleukin-2 in Patients with Melanoma or Renal Cell Carcinoma , 2006, Clinical Cancer Research.

[22]  G. Glinsky.  Genomic Models of Metastatic Cancer: Functional Analysis of Death-from-Cancer Signature Genes Reveals Aneuploid, Anoikis-Resistant, Metastasis-Enabling Phenotype with Altered Cell Cycle Control and Activated PcG Protein Chromatin Silencing Pathway , 2006, Cell cycle.

[23]  J. Issa,et al.  Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  J. S. Rao,et al.  Activation of p53/p21Waf1/Cip1 pathway by 5-aza-2'-deoxycytidine inhibits cell proliferation, induces pro-apoptotic genes and mitogen-activated protein kinases in human prostate cancer cells. , 2005, International journal of oncology.

[25]  D. Tindall,et al.  Letter to the Editor: Androgens and Prostate Cancer: Are the Descriptors Valid? , 2005, Cancer biology & therapy.

[26]  Chenguang Wang,et al.  Minireview: Cyclin D1: normal and abnormal functions. , 2004, Endocrinology.

[27]  Chenguang Wang,et al.  Acetylation of nuclear receptors in cellular growth and apoptosis. , 2004, Biochemical pharmacology.

[28]  E. Baldi,et al.  Androgen receptor: good guy or bad guy in prostate cancer invasion? , 2003, Endocrinology.

[29]  P. Pohlmann,et al.  Phase II Trial of Cisplatin Plus Decitabine, a New DNA Hypomethylating Agent, in Patients With Advanced Squamous Cell Carcinoma of the Cervix , 2002, American journal of clinical oncology.

[30]  M. Toyota,et al.  Epigenetic Regulation of Androgen Receptor Gene Expression in Human Prostate Cancers , 2000, Laboratory Investigation.

[31]  J. Sludden,et al.  Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. , 2000, Cancer research.

[32]  J. Norris,et al.  Intracellular Fas ligand expression causes Fas-mediated apoptosis in human prostate cancer cells resistant to monoclonal antibody-induced apoptosis. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[33]  D. Amanatullah,et al.  Cell-cycle dysregulation and the molecular mechanisms of prostate cancer. , 2000, Frontiers in bioscience : a journal and virtual library.

[34]  G. Schwartsmann,et al.  A Phase I Trial of Cisplatin Plus Decitabine, a New DNA-Hypomethylating Agent, in Patients with Advanced Solid Tumors and a Follow-Up Early Phase II Evaluation in Patients with Inoperable Non-Small Cell Lung Cancer , 2000, Investigational New Drugs.

[35]  J. Herman,et al.  Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate cancer cells. , 1998, Cancer research.

[36]  M. Rubin,et al.  Fas ligand is constitutively secreted by prostate cancer cells in vitro. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[37]  G. Miller,et al.  Fas‐mediated apoptosis in seven human prostate cancer cell lines: Correlation with tumor stage , 1998, The Prostate.

[38]  D. Samid,et al.  A Phase II Study of 5-AZA-2'Deoxycytidine (Decitabine) in Hormone Independent Metastatic (D2) Prostate Cancer , 1998, Tumori.

[39]  A. Belldegrun,et al.  Immunosensitization of prostate carcinoma cell lines for lymphocytes (CTL, TIL, LAK)-mediated apoptosis via the Fas-Fas-ligand pathway of cytotoxicity. , 1997, Cellular immunology.

[40]  A. Belldegrun,et al.  Chemosensitization of human prostate carcinoma cell lines to anti-fas-mediated cytotoxicity and apoptosis. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[41]  M. Cohen,et al.  Fas-mediated apoptosis in human prostatic carcinoma cell lines. , 1997, Cancer research.

[42]  M. van Glabbeke,et al.  The EORTC Early Clinical Trials Cooperative Group experience with 5-aza-2'-deoxycytidine (NSC 127716) in patients with colo-rectal, head and neck, renal carcinomas and malignant melanomas. , 1987, European journal of cancer & clinical oncology.

[43]  E. Ricevuto,et al.  Downmodulation of dimethyl transferase activity enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in prostate cancer cells. , 2008, International Journal of Oncology.

[44]  Stephanie Daignault,et al.  Inhibition of DNA methyltransferase activity prevents tumorigenesis in a mouse model of prostate cancer. , 2006, Cancer research.

[45]  M. Peter,et al.  The CD95(APO-1/Fas) DISC and beyond , 2003, Cell Death and Differentiation.

[46]  R. Willemze,et al.  A randomized phase II study on the effects of 5-Aza-2'-deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia: an EORTC Leukemia Cooperative Group phase II study (06893). , 1997, Leukemia.